Company intelligence / Profile preview

Frame Cancer Therapeutics

Amsterdam, NH, Netherlandscurevac.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

Frame Cancer Therapeutics developed a proprietary approach for cancer immunotherapy based on precise analysis of tumor DNA and RNA to identify neoantigens. In December 2021, regulators in the Netherlands approved Frame's clinical trial protocol to evaluate a peptide vaccine in 15 patients with non-small cell lung cancer. The company was acquired by CureVac in June 2022.

Therapeutic areas: Oncology
Modalities: mRNA vaccinesPersonalized cancer vaccines
Industry: Biotech

Drug pipeline

1 asset

FRAME-001

Partnerships

CureVac

Beyond the preview

Go deeper on Frame Cancer Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Frame Cancer Therapeutics.

Explore the full profile